{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lispro-PH20",
    "query": {
      "intervention": "Lispro-PH20"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T01:17:16.775Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00774800",
      "title": "Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Humalog",
          "type": "DRUG"
        },
        {
          "name": "Humulin-R",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human hyaluronidase PH20 (rHuPH20)",
          "type": "DRUG"
        },
        {
          "name": "Liquid meal",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 22,
      "start_date": "2008-10",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-09-07T01:17:16.775Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00774800"
    },
    {
      "nct_id": "NCT01945099",
      "title": "Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "ePID closed loop system",
          "type": "DEVICE"
        },
        {
          "name": "hyaluronidase",
          "type": "DRUG"
        },
        {
          "name": "Lispro-PH20",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 13,
      "start_date": "2013-09",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2022-05-24",
      "last_synced_at": "2026-09-07T01:17:16.775Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01945099"
    },
    {
      "nct_id": "NCT01526733",
      "title": "Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Sham Injection",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human hyaluronidase PH20",
          "type": "DRUG"
        },
        {
          "name": "Insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "Insulin lispro",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 25,
      "start_date": "2011-12",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-09-07T01:17:16.775Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01526733"
    },
    {
      "nct_id": "NCT00916357",
      "title": "Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Humalog",
          "type": "DRUG"
        },
        {
          "name": "Humulin-R",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human hyaluronidase PH20 (rHuPH20)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 23,
      "start_date": "2009-07",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2014-08-18",
      "last_synced_at": "2026-09-07T01:17:16.775Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00916357"
    },
    {
      "nct_id": "NCT00883558",
      "title": "Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Insulin Lispro",
          "type": "DRUG"
        },
        {
          "name": "regular human insulin",
          "type": "DRUG"
        },
        {
          "name": "recombinant human hyaluronidase PH20",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2009-05",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2014-09-08",
      "last_synced_at": "2026-09-07T01:17:16.775Z",
      "location_count": 8,
      "location_summary": "Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Butte",
          "state": "Montana"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00883558"
    },
    {
      "nct_id": "NCT00979875",
      "title": "A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Recombinant human hyaluronidase PH20 (rHuPH20)",
          "type": "DRUG"
        },
        {
          "name": "Insulin lispro",
          "type": "DRUG"
        },
        {
          "name": "Insulin glulisine",
          "type": "DRUG"
        },
        {
          "name": "Insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 14,
      "start_date": "2009-09",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2014-07-14",
      "last_synced_at": "2026-09-07T01:17:16.775Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00979875"
    },
    {
      "nct_id": "NCT00705536",
      "title": "Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Humalog",
          "type": "DRUG"
        },
        {
          "name": "Humulin-R",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human hyaluronidase PH20 (rHuPH20)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 26,
      "start_date": "2007-12",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-09-07T01:17:16.775Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00705536"
    },
    {
      "nct_id": "NCT00803972",
      "title": "Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "rHuPH20",
          "type": "DRUG"
        },
        {
          "name": "Insulin Human Injection",
          "type": "DRUG"
        },
        {
          "name": "Insulin Lispro Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2008-11",
      "completion_date": "2009-08-28",
      "has_results": false,
      "last_update_posted_date": "2018-08-15",
      "last_synced_at": "2026-09-07T01:17:16.775Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00803972"
    },
    {
      "nct_id": "NCT01194245",
      "title": "Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Insulin lispro",
          "type": "DRUG"
        },
        {
          "name": "recombinant human hyaluronidase PH20",
          "type": "DRUG"
        },
        {
          "name": "Insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "Insulin glulisine",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2010-08",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-09-07T01:17:16.775Z",
      "location_count": 19,
      "location_summary": "Escondido, California • La Jolla, California • San Mateo, California + 16 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Mateo",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01194245"
    },
    {
      "nct_id": "NCT01194258",
      "title": "Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type II"
      ],
      "interventions": [
        {
          "name": "Insulin lispro",
          "type": "DRUG"
        },
        {
          "name": "Insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human hyaluronidase PH20",
          "type": "DRUG"
        },
        {
          "name": "Insulin glulisine",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 132,
      "start_date": "2010-08",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2014-08-20",
      "last_synced_at": "2026-09-07T01:17:16.775Z",
      "location_count": 22,
      "location_summary": "Concord, California • Encino, California • Escondido, California + 18 more",
      "locations": [
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "San Mateo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01194258"
    }
  ]
}